#

Dailypharm Live Search Close
  • HIRA, promote 'COVID-19' outcome at OECD
  • by Lee, Hye-Kyung | translator | 2020-05-14 14:21:12
OECD HCQO’s responses to COVID-19 pandemic
COVID-19 discussion focused on quality and outcome

The meeting of the Working Party on Healthcare Quality and Outcomes (HCQO) of Organisation for Economic Co-operation and Development (OECD) was held on 12 May 2020, chaired by Dr.

 

Sun Min Kim, president of Health Insurance Review and Assessment Service (HIRA) of Korea.

 

OECD HCQO was started in 2001 to develop, collect, and compare a set of indicators that reflect a robust picture of healthcare quality across countries using comparable data.

 

HCQO Working party is made up of representatives of OECD countries and international organizations such as WHO, European Commission, International Hospital Federation and ISQua, and more than 100 experts participated in this meeting.

 

HIRA has represented Republic of Korea for OECD HCQO Working Party since 2007, and President Kim has been actively involved from 2009.

 

President Kim was elected as the chairperson of HCQO Working Party for 2019-2020 as the first women and Asian to hold the chair, and re-elected for 2020-2021.

 

Given the unprecedented challenges from global pandemic, the OECD HCQO meeting was held as virtual meeting and dedicated to the health system readiness and COVID-19 response.

 

The meeting was divided into two sessions; overview of HCQO original work streams and health system readiness and COVID-19 response.

 

In Session 1, Dr.

 

Katherine de Bienassis of OECD Secretariat provided brief overview of agenda documents for feedback and committee actions on ongoing HCQO work on people-centered health data systems, performance of integrated care delivery systems, patient-reported indicators survey, broadening the patient safety measurement agenda, quality indicators for end of life care, and process and updates for the HCQO 2020-2021 data collection.

 

The delegates were invited to comment on the progress made and provide written feedback for further discussion on the next HCQO Working Party Meeting in October.

 

In session 2, participants discussed how health system readiness and emergency preparedness fit into the HCQO’s patient safety and health system performance agenda.

 

Dr.

 

NiekKlazinga of OECD Secretariat provided COVID-19 and the work of the HCQO Working Party, noting the importance of health system preparedness and data infrastructure as a component of the patient safety agenda.

 

Emergency management is comprised of four stages and domains - preparedness, response, mitigation, and transition towards recovery.

 

At this stage, a number of countries beyond the peak of pandemic, health systems should be ready to address challenges in transition towards recovery.

 

COVID-19 poses dual challenges for health care quality and outcomes to ensure high quality, safe and coordinated care both for COVID-19 and non-COVID patients.

 

The transition phase may last more than a year and health systems have to balance the increased demands of acute care related COVID-19 with on-going needs of healthcare system to maintain and provide essential services for all non-COVID patients including but not limited to vaccination, chronic care and cancer care.

 

Next with the Secretariat, selected three countries shared their experiences in response to the COVID-19 pandemic.

 

Dr.

 

Kim representing Republic of Korea provided country kick-off presentation on national response to COVID-19 utilizing real-time healthcare resource and claims data to detect high-risk group, prevent spread in community, collect patient information centrally, and monitor the status of resources including negative pressure isolation room, mask and drug supply.

 

Representative of Australian Commission on Safety and Quality in Healthcare shared the national containment and mitigation strategies and measurement of health system approach.

 

Finnish representative provided national data registries on hospital discharge and intensive care and pilot patient data repository to highlight the data collection and utilization.

 

The delegates carried out a poll on their national experiences in data infrastructure, patient safety and integrated care to tackle the pandemic.

 

As a result of polling, it was significantly noted that all participating countries faced safety challenges regarding COVID-19 in long-term care and ensuring the safety of healthcare workforce, technologies and supplies which were rooted from massive outbreak in long-term care setting and shortage in supplies.

 

The participants provided a comprehensive opinion on the capacity of health data infrastructure including timely data collection, person-based data generation, new or improved data linkage to deal with COVID-19, as well as privacy concerns about personal data use.

 

Lastly, the polling results addressed the importance of integrated care approach to track patient outcomes outside of the hospital, monitor the flow of COVID-19 and non-COVID patients, and emphasize the role of primary care during the mitigation phase of the crisis.

 

The OECD HCQO will continuously work together to measure health system resilience and readiness to strengthen collaboration and generate potential candidates for international benchmarking and further OECD analysis.

 

In this regard, Dr.

 

Kim, as a chairperson of OECD HCQO Working Party and a president of HIRA, said that she would share institutional experiences and lessons of HIRA with global communities and support for member countries’ policy to tackle the pandemic and global health crisis.

 

  • 0
Reader Comment
0
Member comment Write Operate Rule
Colse

댓글 운영방식은

댓글은 실명게재와 익명게재 방식이 있으며, 실명은 이름과 아이디가 노출됩니다. 익명은 필명으로 등록 가능하며, 대댓글은 익명으로 등록 가능합니다.

댓글 노출방식은

댓글 명예자문위원(팜-코니언-필기모양 아이콘)으로 위촉된 데일리팜 회원의 댓글은 ‘게시판형 보기’와 ’펼쳐보기형’ 리스트에서 항상 최상단에 노출됩니다. 새로운 댓글을 올리는 일반회원은 ‘게시판형’과 ‘펼쳐보기형’ 모두 팜코니언 회원이 쓴 댓글의 하단에 실시간 노출됩니다.

댓글의 삭제 기준은

다음의 경우 사전 통보없이 삭제하고 아이디 이용정지 또는 영구 가입제한이 될 수도 있습니다.

  • 저작권·인격권 등 타인의 권리를 침해하는 경우

    상용 프로그램의 등록과 게재, 배포를 안내하는 게시물

    타인 또는 제3자의 저작권 및 기타 권리를 침해한 내용을 담은 게시물

  • 근거 없는 비방·명예를 훼손하는 게시물

    특정 이용자 및 개인에 대한 인신 공격적인 내용의 글 및 직접적인 욕설이 사용된 경우

    특정 지역 및 종교간의 감정대립을 조장하는 내용

    사실 확인이 안된 소문을 유포 시키는 경우

    욕설과 비어, 속어를 담은 내용

    정당법 및 공직선거법, 관계 법령에 저촉되는 경우(선관위 요청 시 즉시 삭제)

    특정 지역이나 단체를 비하하는 경우

    특정인의 명예를 훼손하여 해당인이 삭제를 요청하는 경우

    특정인의 개인정보(주민등록번호, 전화, 상세주소 등)를 무단으로 게시하는 경우

    타인의 ID 혹은 닉네임을 도용하는 경우

  • 게시판 특성상 제한되는 내용

    서비스 주제와 맞지 않는 내용의 글을 게재한 경우

    동일 내용의 연속 게재 및 여러 기사에 중복 게재한 경우

    부분적으로 변경하여 반복 게재하는 경우도 포함

    제목과 관련 없는 내용의 게시물, 제목과 본문이 무관한 경우

    돈벌기 및 직·간접 상업적 목적의 내용이 포함된 게시물

    게시물 읽기 유도 등을 위해 내용과 무관한 제목을 사용한 경우

  • 수사기관 등의 공식적인 요청이 있는 경우

  • 기타사항

    각 서비스의 필요성에 따라 미리 공지한 경우

    기타 법률에 저촉되는 정보 게재를 목적으로 할 경우

    기타 원만한 운영을 위해 운영자가 필요하다고 판단되는 내용

  • 사실 관계 확인 후 삭제

    저작권자로부터 허락받지 않은 내용을 무단 게재, 복제, 배포하는 경우

    타인의 초상권을 침해하거나 개인정보를 유출하는 경우

    당사에 제공한 이용자의 정보가 허위인 경우 (타인의 ID, 비밀번호 도용 등)

  • ※이상의 내용중 일부 사항에 적용될 경우 이용약관 및 관련 법률에 의해 제재를 받으실 수도 있으며, 민·형사상 처벌을 받을 수도 있습니다.

    ※위에 명시되지 않은 내용이더라도 불법적인 내용으로 판단되거나 데일리팜 서비스에 바람직하지 않다고 판단되는 경우는 선 조치 이후 본 관리 기준을 수정 공시하겠습니다.

    ※기타 문의 사항은 데일리팜 운영자에게 연락주십시오. 메일 주소는 dailypharm@dailypharm.com입니다.

If you want to see the full article, please JOIN US (click)